HC Wainwright Predicts Lower Earnings for X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities researchers at HC Wainwright reduced their FY2024 earnings estimates for shares of X4 Pharmaceuticals in a research report issued on Thursday, November 14th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.66) for the year, down from their previous estimate of ($0.60). HC Wainwright currently has a "Buy" rating and a $1.50 target price on the stock. The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals' Q4 2024 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.14) EPS and FY2028 earnings at $0.04 EPS.

Separately, Stifel Nicolaus lowered their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday.

X4 Pharmaceuticals Stock Down 8.3 %

NASDAQ:XFOR traded down $0.03 during mid-day trading on Monday, hitting $0.37. 3,026,267 shares of the company's stock were exchanged, compared to its average volume of 2,355,146. X4 Pharmaceuticals has a one year low of $0.26 and a one year high of $1.60. The business has a fifty day moving average price of $0.58 and a 200 day moving average price of $0.74. The company has a market cap of $63.12 million, a PE ratio of -4.48 and a beta of 0.39. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 6.04.

Insider Transactions at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 230,645 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $126,854.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Mary Dibiase sold 67,695 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the completion of the transaction, the chief operating officer now owns 452,060 shares of the company's stock, valued at approximately $257,674.20. This trade represents a 13.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 580,800 shares of company stock valued at $321,447 in the last ninety days. Corporate insiders own 1.62% of the company's stock.

Institutional Trading of X4 Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its stake in shares of X4 Pharmaceuticals by 46.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company's stock valued at $55,000 after acquiring an additional 12,514 shares during the period. Rhumbline Advisers grew its holdings in X4 Pharmaceuticals by 14.6% during the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company's stock valued at $109,000 after purchasing an additional 23,831 shares during the last quarter. Verition Fund Management LLC purchased a new stake in X4 Pharmaceuticals in the 3rd quarter worth about $30,000. XTX Topco Ltd lifted its stake in X4 Pharmaceuticals by 41.7% in the third quarter. XTX Topco Ltd now owns 157,642 shares of the company's stock worth $106,000 after purchasing an additional 46,397 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of X4 Pharmaceuticals during the third quarter valued at approximately $37,000. 72.03% of the stock is currently owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.